Merck stock slides
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Below are the earnings highlights for Merck & Co Inc. (MRK): Earnings: $3.743 billion in Q4 vs. -$1.226 billion in the same period ...
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...
Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback